Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.11
- Piotroski Score 4.00
- Grade Outperform
- Symbol (AORT)
- Company Artivion, Inc.
- Price $28.27
- Changes Percentage (0.84%)
- Change $0.24
- Day Low $28.03
- Day High $28.77
- Year High $30.00
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
- Last Earnings 10/22/2015
- Ex-Dividend for 5/16 Dividend 12/09/2015
- Dividend Payable 12/18/2015
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $33.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.24
- Trailing P/E Ratio -97.25
- Forward P/E Ratio -97.25
- P/E Growth -97.25
- Net Income $-30,690,000
Income Statement
Quarterly
Annual
Latest News of AORT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Endospan hits enrolment milestone in aortic arch stent trial
Endospan has completed enrollment in a clinical trial for its NEXUS stent graft treating aortic arch disease. The trial aims to support FDA approval and enhance patient outcomes. The company raised $2...
By Yahoo! Finance | 1 month ago -
Echo IQ Shares Surge 25% After FDA Clears AI Solution for Aortic Stenosis
Australian biotech firm Echo IQ saw a 25% surge in stock price after receiving FDA clearance for its AI-driven cardiovascular diagnostic tool. The company is set to capitalize on commercial opportunit...
By Yahoo! Finance | 1 month ago -
Artivion's (NYSE:AORT) Returns Have Hit A Wall
To find potential multi-bagger investments, look for companies with increasing Return on Capital Employed (ROCE) and growing capital employed. Artivion's ROCE of 3.0% underperforms the industry averag...
By Yahoo! Finance | 5 months ago
